English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/128923
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 21 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Título

Acid ceramidase as a therapeutic target in metastatic prostate cancer

AutorCamacho, Luz; Meca-Cortés, Óscar ; Abad, José Luis; García, Simón; Rubio, Nuria; Celià-Terrassa, Toni ; Cingolani, Francesca; Blanco, Jerónimo; Delgado, Antonio; Casas, Josefina; Thomson, Timothy M.
Palabras claveInhibitors
Ceramide
Metastasis
Fecha de publicación19-feb-2013
EditorAmerican Society for Biochemistry and Molecular Biology
CitaciónJournal of Lipid Research 54(5): 1207-1220 (2013)
ResumenAcid ceramidase (AC) catalyzes the hydrolysis of ceramide into sphingosine, in turn a substrate of sphingosine kinases that catalyze its conversion into the mitogenic sphingosine- 1-phosphate. AC is expressed at high levels in several tumor types and has been proposed as a cancer therapeutic target. Using a model derived from PC-3 prostate cancer cells, the highly tumorigenic, metastatic, and chemoresistant clone PC-3/Mc expressed higher levels of the AC ASAH1 than the nonmetastatic clone PC-3/S. Stable knockdown of ASAH1 in PC-3/Mc cells caused an accumulation of ceramides, inhibition of clonogenic potential, increased requirement for growth factors, and inhibition of tumorigenesis and lung metastases. We developed de novo ASAH1 inhibitors, which also caused a dose-dependent accumulation of ceramides in PC-3/Mc cells and inhibited their growth and clonogenicity. Finally, immunohistochemical analysis of primary prostate cancer samples showed that higher levels of ASAH1 were associated with more advanced stages of this neoplasia. These observations confirm ASAH1 as a therapeutic target in advanced and chemoresistant forms of prostate cancer and suggest that our new potent and specific AC inhibitors could act by counteracting critical growth properties of these highly aggressive tumor cells. Copyright © 2013 by the American Society for Biochemistry and Molecular Biology, Inc.
Versión del editorhttp://dx.doi.org/10.1194/jlr.M032375
URIhttp://hdl.handle.net/10261/128923
DOI10.1194/jlr.M032375
Identificadoresdoi: 10.1194/jlr.M032375
issn: 0022-2275
Aparece en las colecciones: (IQAC) Artículos
(CIC) Artículos
(IBMB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.